Recent posts

TypePostAuthorRepliesLast updated
Blog entrySCCR 33 More General Statements re the Agenda items Manon Ress027 weeks 2 days ago
Blog entrySCCR 33 Selected General Statement by India for Asia Pacific and Chile for GRULAC Manon Ress027 weeks 2 days ago
Blog entrySCCR 33. November 14, 2016 Agenda and Schedule Manon Ress027 weeks 2 days ago
Blog entry8 November 2016 - TRIPS Council - India's intervention on the Paragraph 6 Mechanism thiru027 weeks 2 days ago
Blog entry9 November 2016 - WTO TRIPS Council - EU's intervention on the Report of the UN High-Level Panel on Access to Medicines thiru027 weeks 5 days ago
Blog entry9 November 2016 - WTO TRIPS Council - EU's intervention on Intellectual Property and Innovation - Regional Innovation Models thiru027 weeks 5 days ago
Blog entry9 November 2016 - WTO TRIPS Council - UNCTAD's statement on the Report of the UN High-Level Panel on Access to Medicines thiru027 weeks 5 days ago
Blog entryNIH to taxpayers — we don't care about high prices in US for Xtandi. KEI Staff027 weeks 6 days ago
Blog entryIndia Patent Office denies patent for prostate cancer drug sold under brand name Xtandi, generic name enzalutamide James Love027 weeks 6 days ago
Blog entry9 November 2016 - WTO TRIPS Council - WHO's intervention on the Report of the UN High-Level Panel on Access to Medicines thiru027 weeks 6 days ago
Blog entry9 November 2016 - WTO TRIPS Council - India's intervention on the Report of the UN High-Level Panel on Access to Medicines thiru027 weeks 6 days ago
Blog entry9 November 2016 - WTO TRIPS Council - Brazil's intervention on the Report of the UN High-Level Panel on Access to Medicines thiru028 weeks 52 min ago
Blog entryLancet Commission on Essential Medicines Policies publishes 74 page report, endorses delinkage of R&D costs from drug prices James Love028 weeks 1 day ago
Blog entryWHO to Colombia Minister of Health: Unaffordable drug prices are a legitimate reason for issuing a compulsory license Andrew Goldman028 weeks 2 days ago
Blog entrySome measures that a new President and/or Congress can take to lower drug prices in the near term James Love029 weeks 6 hours ago
Blog entryWTO TRIPS Council - Brazil, China, India and South Africa request discussion of the UN High-Level Panel on Access to Medicines Staff029 weeks 1 day ago
Blog entryHIV revenues and industry investments in clinical trials for HIV James Love029 weeks 2 days ago
Blog entryRelative prices of brand and generic drugs James Love029 weeks 2 days ago
Blog entryWashington Monthly Cover Story Highlights Petition to Lower Price of Xtandi in U.S. KEI Staff029 weeks 5 days ago
Blog entryExtending Bayh-Dole March-in rights James Love029 weeks 6 days ago
Blog entryFace time is policy: Appointment logs for USTR officials Froman, Holleyman and Punke, through July 2016 James Love030 weeks 5 hours ago
Blog entry56 NGOs ask US Government enable export of low cost generic versions Xtandi to developing countries Zack Struver030 weeks 2 days ago
Blog entryKite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute Zack Struver030 weeks 5 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Dedalus Pharma, LLC Diane Singhroy030 weeks 6 days ago
Blog entry17 October 2016: USTR Ambassador Michael Froman's reflections on the United Nations High-Level Panel on Access to Medicines thiru031 weeks 9 hours ago